BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Brookline Capital Markets has lowered its price target on Dare Bioscience (NASDAQ:DARE) to $11.00 from $14.00 while maintaining a Buy rating on the stock. Trading at $2.11, the stock has shown resilience with an 11.7% gain over the past week, though it remains well below analyst targets ranging from $12 to $14.
The adjustment follows Dare’s second-quarter update, which Brookline described as "less informative than expected." The firm noted that while Dare continues with plans to bring several products to market via the 503B pathway, including Sildenafil Cream, DARE-HRT1, and two vaginal probiotics, the company did not provide anticipated details about 503B partners and related strategies. InvestingPro data reveals the company’s weak financial health score of 1.64, with a concerning current ratio of 0.34.
Brookline cited positive preliminary data from the Phase 3 Ovaprene trial but expressed concern about a pause or potential termination of the trial’s NIH funding, which could increase costs and extend the timeline to final readout.
The research firm acknowledged that capital inflows of $23 million following the quarter’s end have extended Dare’s financial runway by up to one year.
The price target reduction reflects higher anticipated Ovaprene development costs and dilution from ATM (at-the-market) transactions, according to Brookline Capital Markets.
In other recent news, Dare Bioscience reported its Q2 2025 financial results, highlighting significant developments in its financial strategy and product pipeline. The company addressed a working capital deficit of $12.6 million by raising $17.6 million through stock sales and securing a $6 million grant payment after the quarter ended. These financial maneuvers are part of Dare Bioscience’s efforts to strengthen its position in the market. Additionally, the company continues to focus on strategic product launches and clinical trials, which are pivotal for its ongoing growth in women’s health solutions. Despite these advancements, the stock price experienced a slight decline, although this article will not delve into stock price movements. These updates underscore Dare Bioscience’s active engagement in expanding its market presence and addressing financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.